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“Atypical” pneumonia was described as a distinct and mild form of community-acquired
pneumonia (CAP) already before Mycoplasma pneumoniae had been discovered and
recognized as its cause. M. pneumoniae is detected in CAP patients most frequently
among school-aged children from 5 to 15 years of age, with a decline after adolescence
and tapering off in adulthood. Detection rates by polymerase chain reaction (PCR) or
serology in children with CAP admitted to the hospital amount 4–39%. Although the
infection is generally mild and self-limiting, patients of every age can develop severe
or extrapulmonary disease. Recent studies indicate that high rates of healthy children
carry M. pneumoniae in the upper respiratory tract and that current diagnostic PCR or
serology cannot discriminate between M. pneumoniae infection and carriage. Further,
symptoms and radiologic features are not specific for M. pneumoniae infection. Thus,
patients may be unnecessarily treated with antimicrobials against M. pneumoniae.
Macrolides are the first-line antibiotics for this entity in children younger than 8 years
of age. Overall macrolides are extensively used worldwide, and this has led to the
emergence of macrolide-resistant M. pneumoniae, which may be associated with
severe clinical features and more extrapulmonary complications. This review focuses
on the characteristics of M. pneumoniae infections in children, and exemplifies that
simple clinical decision rules may help identifying children at high risk for CAP due to
M. pneumoniae. This may aid physicians in prescribing appropriate first-line antibiotics,
since current diagnostic tests for M. pneumoniae infection are not reliably predictive.
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INTRODUCTION
The clinical entity of “atypical” pneumonia was recognized in the 1930s many years before the
etiological agent was established (McCoy, 1946). The term separated this entity of pneumonia
from classical pneumococcal pneumonia due to its lack of response to available antibiotics and the
distinct clinical presentation without typical lobar pneumonia and a less severe disease course. That
is why the term “walking pneumonia” has been introduced to denote this mild form of pneumonia.
It was in a patient with “atypical” pneumonia in 1944, where Mycoplasma pneumoniae was
first isolated from sputum in tissue culture by Eaton et al. (1944). At that time, it was believed to
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be a virus because it was resistant to penicillin and sulfonamides
and passed through bacteria-retaining filters. Experiments with
Marine recruits and adult prisoners demonstrated that the so-
called Eaton agent caused lower respiratory tract infections in
humans (Chanock et al., 1961a,b). In 1963, it was first cultured
on cell-free medium and classified as M. pneumoniae (Chanock
et al., 1962; Chanock, 1963). Today we know that mycoplasmas
are prokaryotes that lack a cell wall and represent the smallest
self-replicating organisms (Figure 1). With a size of 816,394 base
pairs, the genome of M. pneumoniae is at least five times smaller
than that of Escherichia coli (Himmelreich et al., 1996). The
absence of a cell wall and the specialized attachment organelle
facilitate close contact with the host respiratory epithelium, which
supplies the bacterium with the necessary nutrients for its growth
and proliferation.
Mycoplasma pneumoniae causes both upper and lower
respiratory tract infections, with community-acquired
pneumonia (CAP) as the major burden of disease. Although
M. pneumoniae infections are generally mild and self-limiting,
patients of every age can develop severe and fulminant
disease (Kannan et al., 2012). M. pneumoniae can also cause
extrapulmonary manifestations that affect almost every organ
(Narita, 2010).
In children, M. pneumoniae infections were first reported in
1960 when 16% of 110 children with lower respiratory tract
disease were tested positive by a fourfold rise in antibody titers
against the Eaton agent (Chanock et al., 1960). To date, it
is known that the incidence of M. pneumoniae infections is
generally higher in children than in adults (Foy et al., 1979).
This review focuses on the characteristics of M. pneumoniae
infections in children, and discusses simple clinical decision rules
that may further aid clinicians in identifying patients at high risk
for M. pneumoniae CAP.
EPIDEMIOLOGY
Mycoplasma pneumoniae is transmitted by respiratory droplets
through close contact. The incubation period can be long
FIGURE 1 | M. pneumoniae morphology in vitro. Scanning electron
micrograph of M. pneumoniae strain Mac (subtype 2).
from 1 up to 3 weeks. Outbreaks have been reported within
families, schools, universities, institutions, camps, and military
bases. Family members of index patients with acute respiratory
infection and detection of M. pneumoniae in the upper
respiratory tract were found positive in 15% by polymerase chain
reaction (PCR) (Dorigo-Zetsma et al., 2001). Thereof, 75% were
<16 years of age and 44% did not develop any respiratory
symptoms. At universities, the largest outbreak within 35 years
in the U.S. was observed during September 1–December 4, 2012,
where a total of 83 CAP cases were identified among students, and
12 out of 19 tested cases (63%) were positive for M. pneumoniae
by quantitative real-time PCR (Centers for Disease Control and
Prevention [CDC], 2013).
Outbreaks appear mainly during M. pneumoniae epidemics
that occur in 3–7 years cycles, in addition to a background
endemic pattern (Jacobs, 2012). The most recent epidemic
in Europe occurred in 2010–2012 with a peak incidence in
Finland of 145/100,000 cases in 2011 (Polkowska et al., 2012;
Jacobs et al., 2015). The cyclic occurrence of epidemics may
be facilitated by a decreasing herd immunity and different
M. pneumoniae genotypes circulating in the human population
(Jacobs, 2012). The two major circulating genotypes, or subtypes,
of M. pneumoniae are indicated as subtype 1 and 2. Differences
between these subtypes in the amino acid sequence of the
major adhesion protein P1 are believed to play a role in the
epidemiology of infections with M. pneumoniae (Su et al., 1990;
Vink et al., 2012). The differences between the 169-kDa P1
proteins of subtype 1 and 2 isolates were found to be concentrated
in two specific amino acid stretches within the protein. These
regions are encoded by two DNA elements within the P1 gene,
i.e., repetitive elements RepMP2/3 and RepMP4. The RepMP2/3
and RepMP4 are not unique to the P1 gene, but are also found at
other sites within the bacterial genome (Spuesens et al., 2009).
Homologous recombination events between these repetitive
elements, which are similar to each other, but not identical,
may form the basis of antigenic variation of the P1 protein of
M. pneumoniae (Vink et al., 2012). While such recombination
events may induce antigenic variation within subtype 1 or
subtype 2 strains, M. pneumoniae strains cannot switch from one
subtype to the other, as the entire set of RepMP elements found
in one subtype differs significantly from those found in the other
subtype. Moreover, changes in the proportion of the two subtypes
of M. pneumoniae were not observed between 2003 and 2012 in
Europe (Jacobs et al., 2015).
INFECTION
Respiratory Disease
Although CAP is the major burden of disease, milder clinical
presentations of M. pneumoniae respiratory infections may be
much more common than CAP. These include acute bronchitis
and upper respiratory tract infections (Esposito et al., 2000, 2002).
M. pneumoniae could be detected by PCR and/or serology in 24%
of non-streptococcal pharyngitis cases (Esposito et al., 2002).
It is estimated that 3–10% of children with M. pneumoniae
respiratory infection develop CAP and that<5% of CAP cases are
Frontiers in Microbiology | www.frontiersin.org 2 March 2016 | Volume 7 | Article 329
fmicb-07-00329 March 21, 2016 Time: 17:25 # 3
Meyer Sauteur et al. Mycoplasma pneumoniae in Children
severe enough to require hospitalization (Waites and Talkington,
2004). Between 1963 and 1975, M. pneumoniae was detected
by culture of respiratory specimens and/or a fourfold titer rise
in complement fixation test (CFT) in 15–20% of radiologically
confirmed CAP cases in Seattle, U.S. (Foy et al., 1979). In
subsequent etiological studies, M. pneumoniae accounted for
4–39% of the isolates identified by PCR and/or serology in
children with CAP admitted to the hospital (Juven et al., 2000;
Principi et al., 2001; Baer et al., 2003; Michelow et al., 2004).
M. pneumoniae was first reported as the most common bacterial
cause of CAP in children requiring hospitalization in a U.S.
multicenter study from 2011 to 2012 in Nashville and Salt Lake
City (Jain et al., 2015). In this study, M. pneumoniae could be
detected by PCR in 178 (8%) out of 2179 cases with CAP, whereas
Streptococcus pneumoniae was found in 79 cases (4%).
Manifest upper and/or lower respiratory tract infections
with M. pneumoniae occur at all ages (Foy et al., 1979).
Recent observations have indicated that M. pneumoniae has
also a relatively high prevalence in the respiratory tract of
children <5 years (Principi et al., 2001; Gadsby et al., 2012).
M. pneumoniae CAP, however, was reported to be most frequent
among school-aged children from 5 to 15 years of age, with a
decline after adolescence and tapering off in adulthood (Figure 2)
(Foy et al., 1979). This notion was corroborated in the recent CAP
study in the U.S., where M. pneumoniae was detected significantly
more frequent in children ≥5 years of age than in younger
children (19% vs. 3%) (Jain et al., 2015).
In addition to the presentation at school-age, children with
CAP due to M. pneumoniae have been found to present with
a significantly longer duration of fever compared with other
children with CAP (Fischer et al., 2002). Other symptoms that
may be associated with M. pneumoniae CAP are the absence
of wheeze and the presence of chest pain (Wang et al., 2012).
However, there is still a paucity of high quality data regarding
clinical signs and symptoms associated with M. pneumoniae
infections. A recent Cochrane review therefore concluded that
FIGURE 2 | Detection of M. pneumoniae in community-acquired
pneumonia (CAP) according to age group. Infection was diagnosed by
culture of respiratory specimens and/or a fourfold titer rise in complement
fixation test (CFT). Adapted with permission from Foy et al. (1979).
the absence or presence of individual clinical symptoms or
signs cannot be used to help clinicians accurately diagnose
M. pneumoniae in children and adolescents with CAP (Wang
et al., 2012).
Pathogenic effects in the respiratory tract may be caused by
M. pneumoniae either directly (by active infection), indirectly
(by infection-induced immune mechanisms), or both (Narita,
2010). M. pneumoniae causes direct injury through the
generation of activated oxygen. A potential candidate protein
of M. pneumoniae that may be involved in causing direct
damage to the respiratory tract is a pertussis toxin-like protein
termed Community-Acquired Respiratory Distress Syndrome
(CARDS) toxin (Kannan and Baseman, 2006; Becker et al., 2015).
A recombinant version of the CARDS toxin has been shown to
bind with high affinity to surfactant protein A and to exhibit
mono-ADP ribosyltransferase and vacuolating activities, which
causes disruption of the respiratory epithelium in animal models
(Kannan and Baseman, 2006).
In addition to the direct damage resulting from infection by
M. pneumoniae, the immunological response following infection
generates inflammatory reactions that may cause pulmonary
and extrapulmonary symptoms. More severe symptoms of CAP
have been observed in older children and adolescents (Waites
and Talkington, 2004). This suggests that the age-dependent
magnitude and nature of inflammatory responses in childhood
may be a major factor contributing to the development of
M. pneumoniae-associated disease, similar to what is observed,
e.g., in infectious mononucleosis or rheumatic fever. In fact, the
severity of M. pneumoniae CAP in children was closely associated
with increased concentrations of interleukin (IL)-8 and IL-18 in
acute phase serum and pleural fluid samples (Narita and Tanaka,
2007). In addition, it has been demonstrated that cell-mediated
immunity contributes to the pathogenesis of M. pneumoniae
CAP, as it was shown that the severity of CAP correlated
positively with the size of a cutaneous induration following
intradermal injection of M. pneumoniae antigens (Mizutani et al.,
1971). This study described 20 patients with CAP, of which 19
were children 4–15 years of age, diagnosed by a significant rise in
antibody titers against M. pneumoniae with CFT. The strongest
skin reactions were seen in patients with severe CAP.
Asthma
Mycoplasma pneumoniae and other “atypical bacteria” have long
been implicated in the pathogenesis of asthma (Atkinson, 2013).
There are many studies that have addressed this issue in the
recent past. In an observational study on children and adults
with asthma, M. pneumoniae infection was diagnosed in 9% of
children with asthma (24/256) and was found more frequent in
patients with chronic asthma (14%) than in those with asthma
exacerbations (7%; p = 0.10) (Bebear et al., 2014). The diagnosis
of M. pneumoniae infection in this study was performed by PCR
and/or serology. Another recent study diagnosed M. pneumoniae
in children with acute asthma (64%, 34/53) and refractory asthma
(65%, 17/26), as well as in healthy controls (56%, 36/64), but
did not find significant differences between these three groups
(Wood et al., 2013). The high detection rates reported in this
study were obtained using novel diagnostic methods [CARDS
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toxin enzyme immunoassay (EIA) and CARDS gene-specific
PCR] (Wood et al., 2013). In a recent Taiwanese study (Yeh
et al., 2015), 1591 children and adults with M. pneumoniae
infection, diagnosed by positive immunoglobulin (Ig) M or
fourfold IgG titer increase, but without prior asthma history were
included from 2000 to 2008 and followed until the diagnosis of
asthma or the end of 2011. Compared to matched 6364 patients
without M. pneumoniae infection, the cumulative incidence
of asthma was significantly higher in the M. pneumoniae
cohort than in the control cohort (p < 0.0001). Patients with
M. pneumoniae infection were at higher risk of having early-
onset asthma (age at asthma diagnosis <12 years) and late-
onset asthma (age at asthma diagnosis ≥12 years). These most
recent findings suggested that M. pneumoniae can induce airway
inflammation and contribute to incident asthma. Interestingly,
exposure to recombinant CARDS toxin resulted in an allergic-
type inflammatory response and airway hyperreactivity in mice
and baboons (Hardy et al., 2009; Medina et al., 2012). It will be
interesting to investigate whether CARDS toxins induce a similar
allergic response during M. pneumoniae infections.
Extrapulmonary Manifestations
Apart from the respiratory tract infection, M. pneumoniae
can cause extrapulmonary manifestations in almost every
organ, including the skin and the hematologic, cardiovascular,
musculoskeletal, and nervous systems (Narita, 2010). These
manifestations may be caused either by direct local effects of
M. pneumoniae, after dissemination of the bacteria throughout
the body, or indirect effects, such as autoimmune reactions. The
most frequent manifestations are diseases of the dermatologic
and nervous system.
Skin manifestations occur in up to 25% of all M. pneumoniae
infections, including mostly non-specific exanthems, erythema
nodosum, urticaria, Stevens–Johnson syndrome, and a rare
but distinct disorder with prominent mucous membrane
involvement denominated as M. pneumoniae-associated
mucositis (MPAM) (Schalock and Dinulos, 2009; Meyer Sauteur
et al., 2012). This condition was first described by Fuchs (1876),
and therefore also referred to as Fuchs syndrome (Meyer Sauteur
et al., 2011). A recent review identified 32 patients with MPAM
at a median age of 13.5 years at presentation (range 3–38 years,
23 children or young adolescents ≤18 years) (Meyer Sauteur
et al., 2012). All patients presented with prodromal respiratory
symptoms with a median duration of 7 days, and pneumonia was
found in chest radiography in 79%. Oral lesions were present in
all cases (Figure 3), ocular lesions in 97%, and urogenital lesions
in 78%. There were no skin lesions in 69%. Although 12% of the
patients were admitted to the intensive care unit, no one suffered
from long-term sequelae.
Encephalitis and Guillain–Barré syndrome (GBS) constitute
the most common and severe neurologic manifestations, where
M. pneumoniae infection is established in up to 10 and 15% of
patients, respectively (Bitnun et al., 2001; Sinha et al., 2007). In
M. pneumoniae-associated encephalitis, both a direct infection
of the central nervous system (CNS) and an immune-mediated
process have been implied to be involved (Narita, 2009). Because
the detection rate of M. pneumoniae by PCR in cerebrospinal
FIGURE 3 | M. pneumoniae-associated mucositis (MPAM). Erosive oral
lesions limited to the mucosa in this form of MPAM in a 24-year-old woman.
Reprinted with permission from Meyer Sauteur et al. (2012).
fluid (CSF) of M. pneumoniae encephalitis patients is relatively
low (0–14%) (Bitnun et al., 2001; Daxboeck et al., 2004; Christie
et al., 2007a; Domenech et al., 2009), a significant proportion of
the cases is believed to be immune-mediated. This is supported by
the finding that various cases with M. pneumoniae encephalitis
in which bacterial DNA could not be detected in CSF had a
more prolonged duration of respiratory symptoms before the
onset of encephalitis (>5–7 days) (Bitnun et al., 2001; Narita
and Yamada, 2001; Daxboeck et al., 2004). These cases indicate
that M. pneumoniae encephalitis represents a postinfectious
disorder, which manifests after clearance of the bacteria from
the CNS or respiratory tract by the immune system (Meyer
Sauteur et al., 2014b). A recent study presented 365 children with
M. pneumoniae detected in the respiratory tract or CSF by PCR,
22 (6%) of whom had encephalitis (1996–2013, Toronto, ON,
Canada) (Al-Zaidy et al., 2015). Interestingly, patients in which
M. pneumoniae was detectable in the respiratory tract but not
in CSF showed pulmonary infiltrates on chest radiograph more
frequently than patients with positive PCR in CSF (77% vs. 33%).
This suggests that pneumonia may be an indicator for a remote
inflammatory process in M. pneumoniae encephalitis patients,
which was also shown in 83% (5/6) of children observed during a
national surveillance, all with negative PCR in CSF (2010–2015,
Switzerland) (Meyer Sauteur et al., 2016) (Figure 4).
Mycoplasma pneumoniae expresses adhesion proteins and
glycolipids that share structural homology with a variety of
host cells (molecular mimicry) and may induce cross-reactive
antibodies (Meyer Sauteur et al., 2014b). In children with
M. pneumoniae encephalitis, intrathecal antibodies directed
against galactocerebroside (GalC) were found (Christie et al.,
2007b; Meyer Sauteur et al., 2015a). Of note, all these patients
had a negative PCR in CSF. GalC is a major glycolipid antigen
in the myelin sheath of both the peripheral and CNS neurons
(Menge et al., 2005). In fact, antibodies against M. pneumoniae
infection have been found to cross-react with GalC in GBS
patients (Kusunoki et al., 2001; Ang et al., 2002). Moreover,
anti-GalC antibodies caused demyelinating neuropathy in rabbits
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FIGURE 4 | M. pneumoniae-associated encephalitis. Axial cranial magnetic resonance imaging (MRI) in two children with encephalitis during M. pneumoniae
infection: (A) 5-year-old boy with hyperintensity and generalized edema of the right temporal lobe [T1 weight MRI; patient 1 published in Meyer Sauteur et al. (2016)].
(B) 9-year-old boy with generalized edema of crus posterior of capsula interna [T2 weight MRI; reprinted with permission from Meyer Sauteur et al. (2014c)].
(Saida et al., 1979) and have been associated with demyelination
in GBS (Ang et al., 2002), but also in encephalitis (Christie
et al., 2007b) and encephalomyelitis (Samukawa et al., 2012). The
detection of intrathecal antibodies against M. pneumoniae and
GalC may also be regarded as a promising new diagnostic tool
for M. pneumoniae-associated CNS disease (Meyer Sauteur et al.,
2014b, 2015b).
CARRIAGE
Like many other respiratory pathogens, M. pneumoniae can
be carried asymptomatically in the respiratory tract (Foy,
1993). Recent studies have demonstrated that asymptomatic
carriage of M. pneumoniae is highly prevalent. Detection
rates of M. pneumoniae DNA in the respiratory tract of
healthy children without respiratory symptoms were 21%
in a Dutch study (2008–2011, Rotterdam, The Netherlands)
(Spuesens et al., 2013) and 56% in a U.S. study (2009–2011,
San Antonio, TX, U.S.) (Wood et al., 2013). Longitudinal
sampling of M. pneumoniae–positive asymptomatic children
demonstrated that M. pneumoniae can be present in the upper
respiratory tract without causing disease, for up to 4 months
(Spuesens et al., 2013). The prevalence of M. pneumoniae
in the upper respiratory tract of asymptomatic children
varied considerably between years and seasons. For example,
asymptomatic carriage rates of 3% and 58% were reported
in the spring of 2009 and the summer of 2010, respectively
(Spuesens et al., 2013). These data suggest that carriage follows
an epidemic pattern. It is tempting to speculate that this
fluctuation in prevalence is related to the cyclic epidemics
of M. pneumoniae infections. Apart from M. pneumoniae,
children were found to simultaneously carry many pathogens in
their nose and throat (Spuesens et al., 2013). These pathogens
include the bacteria S. pneumoniae, Staphylococcus aureus,
Moraxella catarrhalis, and Haemophilus influenzae, and the
viruses influenza A/B, human metapneumovirus, respiratory
syncytial virus, parainfluenzavirus, rhinovirus, coronavirus,
bocavirus, and adenovirus. The simultaneous presence of two or
more of these pathogens was detected in 56% of asymptomatic
children (Spuesens et al., 2013).
In children with M. pneumoniae CAP, co-existence of
M. pneumoniae with other pathogens has also been described
(Juven et al., 2000; Michelow et al., 2004), and was recently
reported in 28% of the patients (Jain et al., 2015). The impact of
co-infections in M. pneumoniae CAP on disease severity is not
yet determined.
DIAGNOSIS
Diagnostic Tests
Because the mere presence of M. pneumoniae in the upper
respiratory tract is neither indicative nor predictive for
respiratory disease, the routine diagnostic procedures to detect
acute respiratory infections with M. pneumoniae need to
be reconsidered. An overview of diagnostic tests with their
advantages and drawbacks is shown in Table 1.
Current guidelines (Bradley et al., 2011; Harris et al., 2011)
recommend PCR and single-sample serological tests to diagnose
M. pneumoniae infections. The sensitivity of serological tests
depends on the time point of the first serum and on the
availability of paired sera for seroconversion to IgG and/or rise
in antibody titer. Specific serum IgM emerges within 1 week
after initial infection and about 2 weeks before IgG (Meyer
Sauteur et al., 2014b). Although specific serum IgA arises even
earlier than IgM, it could be detected only in 2% of PCR-
positive children with symptomatic respiratory tract infection
(Spuesens et al., 2013). Cross-reactions with other pathogens
and non-infectious disease has been described for CFT and
particle agglutination assay, but also some EIAs lack the required
sensitivity and specificity (Beersma et al., 2005). Further, it
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FIGURE 5 | A fast-and-frugal clinical decision tree for ruling out M. pneumoniae infection in children with community-acquired pneumonia (CAP).
Clinical features are considered sequentially, with a possible stop decision after each question. Abbreviations: AR, absolute risk; CI, confidence interval. Adapted
from Fischer et al. (2002).
is intriguing that the detection of IgM, as well as IgG and
IgA by EIA could not discriminate between the asymptomatic
and symptomatic groups of children (Spuesens et al., 2013).
The demonstrated positive serological results in asymptomatic
M. pneumoniae PCR-positive children (n = 66; IgM in 17%,
IgG in 24%, and IgA in 6%) may simply reflect one or
more previous encounters with M. pneumoniae and are not
necessarily related to the presence of M. pneumoniae in the
respiratory tract. Thus, it is questionable whether or not a
positive result in these tests actually indicates the etiological
role of M. pneumoniae in all cases. In that sense, the positive
predictive value of these tests may be overestimated, whereas
the negative predictive value may be acceptable (Bradley et al.,
2011).
The “gold standard” for diagnosis of M. pneumoniae infections
is still considered to be a fourfold increase in antibody titer as
measured in paired sera (Gardiner et al., 2015). However, the use
of convalescent sera is not useful in clinical practice because it
is too time-consuming and does not allow clinicians to initiate
treatment protocols in a timely fashion. Clinicians therefore need
to be aware of the implications and clinical significance of a
positive PCR or serology test result.
Clinical Assessment
While diagnostic tests may not be reliably predictive for a
symptomatic M. pneumoniae infection, the clinical assessment
of this entity is being revisited. The British Thoracic Society
guidelines recommend that bacterial pneumonia should be
considered in children when there is persistent or repetitive fever
>38.5◦C together with chest recession and a raised respiratory
rate (Harris et al., 2011). A chest radiograph should not be
considered a routine investigation in children thought to have
CAP. In fact, although bilateral, diffuse infiltrates are common,
none of the radiographic findings associated with M. pneumoniae
CAP is specific (John et al., 2001).
A fast-and-frugal clinical decision tree provided a rapid
probability estimate of the cause of CAP in 253 children
(1 months–16 years; 1997–1999, Zurich, Switzerland) (Fischer
et al., 2002). M. pneumoniae infection was diagnosed in
13% (n = 32) of these children by PCR in respiratory
specimens and serology (seroconversion and/or fourfold rise
in antibody titer). Compared with other children with CAP,
patients with M. pneumoniae were older and had a longer
duration of fever (p < 0.001). Asking the simple question
regarding the age of the child and the duration of fever
allowed identification of the following group at high risk for
CAP due to M. pneumoniae: children with CAP who have
had fever >2 days and who were >3 years of age. The
score model placed 75% of all patients with M. pneumoniae
infection into the high-risk group (Figure 5). These simple rules
may further aid physicians in prescribing appropriate first-line
antibiotics.
TREATMENT AND VACCINES
Antibiotics
In consequence of the diagnostic uncertainty for M. pneumoniae
infections, the British Thoracic Society guidelines suggest empiric
macrolide treatment at any age if there is no response to
first-line β-lactam antibiotics or in the case of very severe
disease (Harris et al., 2011). The lack of a cell wall makes
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FIGURE 6 | Worldwide macrolide-resistant M. pneumoniae (MRMP) rates. Actual MRMP rates are punctually depicted in pie charts (in black) over the world
map. Asia: Japan (2011): 87% (176/202) (Okada et al., 2012), South Korea (2011): 63% (44/70) (Hong et al., 2013), China (2012): 97% (31/32) (Zhao et al., 2013),
Israel (2010): 30% (9/30) (Averbuch et al., 2011); North America: U.S. (2012–2014): 13% (12/91) (Zheng et al., 2015), Canada (2010–2012): 12% (11/91) (Eshaghi
et al., 2013); Europe: The Netherlands (1997–2008): 0% (0/114) (Spuesens et al., 2012), Germany (2003–2008): 1% (2/167) (Dumke et al., 2010), France
(2005–2007): 10% (5/51) (Peuchant et al., 2009), Italy (2010): 26% (11/43) (Chironna et al., 2011), Scotland (2010–2011): 19% (6/32) (Ferguson et al., 2013),
Switzerland (2011–2013): 2% (1/50) (Meyer Sauteur et al., 2014a), England and Wales (2014–2015): 9% (4/43) (Brown et al., 2015).
M. pneumoniae resistant to cell wall synthesis inhibitors such
as β-lactam antibiotics. The antibiotics with the best minimum
inhibitory concentration values against M. pneumoniae include
macrolides, tetracyclines, and fluoroquinolones (Waites and
Talkington, 2004). Although the latter two have a good in vitro
inhibitory effect against M. pneumoniae, tetracyclines may
cause teeth discoloration (Waites and Talkington, 2004) and
fluoroquinolones may affect the developing cartilage in young
children (Adefurin et al., 2011). Thus, they are not recommended
by current guidelines in young children; the age limit for
tetracyclines is ≥8 years, while that of fluoroquinolones is
adolescence with skeletal maturity (Bradley et al., 2011). The
occurrence of arthropathy due to fluoroquinolones, however,
is uncertain, and all musculoskeletal adverse effects reported
in the literature had been reversible following withdrawal
of treatment (Adefurin et al., 2011). The protein synthesis
inhibitors of the macrolide class have a more favorable
side effect profile and are therefore the first-line antibiotics
for M. pneumoniae infections in children (Bradley et al.,
2011).
Although antibiotics are effective against M. pneumoniae
in vitro (Bebear et al., 2011), there is lack of evidence
on their in vivo efficacy. Observational data indicated that
children with CAP due to M. pneumoniae have a shorter
duration of symptoms and fewer relapses when treated
with an antimicrobial agent active against M pneumoniae
(McCracken, 1986; Waites and Talkington, 2004). A recent
Cochrane review evaluated seven studies on the effectiveness
of antibiotic treatment for M. pneumoniae lower respiratory
tract infections in children (Gardiner et al., 2015). However,
the diagnostic criteria, the type and duration of treatment,
inclusion criteria, and outcome measures differed significantly,
making it difficult to draw any specific conclusions, although
one trial suggested that macrolides may be efficacious in
some cases (Esposito et al., 2005). It is clear that studies
on the efficacy of antibiotics rely on a correct diagnosis
of M. pneumoniae infections. Given the aforementioned
shortcomings of current diagnostic tests, conclusions on
the efficacy of antibiotic treatment will have to be re-
examined.
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Antibiotic Resistance
Since 2000, the extensive macrolide use led to an alarming
worldwide increase in the prevalence of macrolide-resistant
M. pneumoniae (MRMP) strains (Bebear et al., 2011). Resistance
is based on specific point mutations in domain V of the 23S rRNA
(at positions 2063, 2064, and 2617), which reduce the affinity of
macrolides to the large subunit (50S) of the bacterial ribosome
(Bebear et al., 2011). MRMP has been observed during macrolide
treatment as a result of antibiotic selective pressure (Cardinale
et al., 2011; Chironna et al., 2011; Saegeman et al., 2012). To
date, macrolide resistance has been detected on a worldwide scale.
MRMP had developed in Asia (Hong et al., 2013), where MRMP
rates have risen as high as 97% in China (Zhao et al., 2013).
MRMP has now also been reported from North America and
Europe (Figure 6).
The clinical relevance of macrolide resistance in hospitalized
children with CAP may lie in prolonging the symptoms of
the disease (Okada et al., 2012; Cardinale et al., 2013; Zhou
et al., 2014). Zhou et al. (2014) found that an increase in
MRMP may also have serious clinical consequences in children,
leading to more severe radiological findings of CAP and even
an increase in extrapulmonary manifestations. In this study,
hospitalized children with CAP due to MRMP developed more
often extrapulmonary disease than children with CAP caused
by macrolide-sensitive strains (30% vs. 10%; p = 0.03) (Zhou
et al., 2014). These manifestations included skin diseases and
nervous system complications in 18% and 7%, respectively,
of the MRMP-infected children. Serum inflammatory cytokine
levels (INF-γ, IL-6, and IP-10) were higher in patients infected
with MRMP than in patients infected with macrolide-sensitive
strains (Matsuda et al., 2013). This suggests that the higher
and more persistent inflammatory stimulation by MRMP may
increase the possibility of severe lung lesions and extrapulmonary
complications.
Vaccines
While previous attempts to produce vaccines on the basis of
inactivated bacteria resulted in limited efficacy against CAP and
various adverse effects (Linchevski et al., 2009), the recent use
of recombinant proteins as potential vaccines was found to be
promising: The immunization of mice with a immunogenic
recombinant protein encompassing the C-terminal part of
the P1 protein (RP14) induced strong mucosal and systemic
antibody responses against M. pneumoniae, and reduced lung
inflammation in infected mice (Zhu et al., 2012). Another
study showed that immunization of guinea pigs with a chimeric
protein consisting of RP14 and the P30 adhesion protein of
M. pneumoniae resulted in a robust antibody response that led
to a reduction in bacterial loads in the respiratory tract (Hausner
et al., 2013).
CONCLUSION
The increasing prevalence of MRMP has become a significant
issue, since MRMP can potentially cause more severe and
even extrapulmonary disease. Because symptoms and radiologic
features of M. pneumoniae CAP seem to be unspecific and
current diagnostic procedures cannot discern between carriage
and infection in a clinically relevant time frame, simple clinical
rules may further aid physicians in prescribing appropriate
first-line antibiotics. Thus, empiric macrolide treatment may be
restricted to children at high risk for M. pneumoniae CAP, i.e.,
children with CAP who have fever>2 days and who are>3 years
of age, or in the case of very severe disease. Future research should
focus on novel aspects of M. pneumoniae-related pathogenesis
resulting in more precise diagnostic tools and tailored treatment
that prevents the emergence of antimicrobial resistance.
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